GlassScriptPhysician profile
Clare M Gomez
NPI 1871292607
$1,562.60
in general payments reported to CMS, 2019-2025
17 companies · $837 in 2025
The $837 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $89.79 · 2024: $636 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.60 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $571.48 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $220.00 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $181.46 | 2024-2025 | |
| Amgen INC. | $106.21 | 2024-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $101.47 | 2023-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $100.44 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $45.20 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $40.92 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.17 | 2024-2025 | Jardiance |
| Pulmonx Corporation | $32.27 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Astellas Pharma US INC | $21.78 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.19 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $19.28 | 2025 | Gemtesa |
| Saluda Medical Americas, INC. | $18.81 | 2024 | Evoke |
| Medtronic, INC. | $18.13 | 2025 | Inceptiv |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.22 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clare Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.